Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its holdings in shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX) by 4.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 456,663 shares of the company’s stock after buying an additional 19,281 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.75% of Pliant Therapeutics worth $5,119,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in PLRX. SG Americas Securities LLC raised its stake in shares of Pliant Therapeutics by 536.3% during the 2nd quarter. SG Americas Securities LLC now owns 45,891 shares of the company’s stock worth $493,000 after buying an additional 38,679 shares during the period. Hennion & Walsh Asset Management Inc. acquired a new position in Pliant Therapeutics in the 2nd quarter valued at $734,000. Bank of New York Mellon Corp raised its stake in Pliant Therapeutics by 14.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 228,693 shares of the company’s stock valued at $2,458,000 after purchasing an additional 29,629 shares during the last quarter. Summit Securities Group LLC acquired a new position in Pliant Therapeutics in the 2nd quarter valued at $59,000. Finally, HighMark Wealth Management LLC raised its stake in Pliant Therapeutics by 58.8% in the 2nd quarter. HighMark Wealth Management LLC now owns 67,500 shares of the company’s stock valued at $726,000 after purchasing an additional 25,000 shares during the last quarter. 97.30% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently commented on PLRX shares. Leerink Partnrs raised Pliant Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. Leerink Partners started coverage on Pliant Therapeutics in a report on Monday, September 9th. They issued an “outperform” rating and a $33.00 target price for the company. Finally, HC Wainwright restated a “buy” rating and issued a $38.00 target price on shares of Pliant Therapeutics in a report on Friday, November 8th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Pliant Therapeutics has a consensus rating of “Buy” and a consensus price target of $40.50.

Pliant Therapeutics Stock Down 2.5 %

Shares of NASDAQ:PLRX opened at $13.85 on Friday. The business has a 50-day moving average price of $13.85 and a 200 day moving average price of $12.76. The company has a current ratio of 10.26, a quick ratio of 10.26 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $842.83 million, a price-to-earnings ratio of -4.15 and a beta of 1.05. Pliant Therapeutics, Inc. has a 12-month low of $10.22 and a 12-month high of $19.62.

Pliant Therapeutics Profile

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.